TY - JOUR
T1 - Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa
AU - Zouboulis, Christos C.
AU - Hansen, Hendrik
AU - Caposiena Caro, Raffaele Dante
AU - Damiani, Giovanni
AU - Delorme, Isabelle
AU - Pascual, José Carlos
AU - Reguiai, Ziad
AU - Trigoni, Anastasia
AU - Vilarrasa, Eva
AU - Roldán, Fernando Alfageme
PY - 2020
Y1 - 2020
N2 - Background: Adalimumab is the only approved compound for the treatment of adult patients with moderate-to-severe hidradenitis suppurativa (HS) who did not respond to a systemic classical treatment. Despite its significant short- and long-term efficacy, a percentage of patients do not respond sufficiently. Moreover, some primary responders experience a response loss with time. Objective: To analyse the effectiveness of adalimumab dose intensification in HS patients. Methods: A case series of adalimumab 80 mg/week subcutaneously (s.c.) compassionate use in patients with HS, who did not respond sufficiently or in primary responders with progressive response loss to the registered adalimumab dose of 40 mg/week s.c. Patients were collected and evaluated retrospectively. Patients' data were extracted from medical records. Results: The 14 patients collected were Caucasian with HS of Hurley stage II-III and moderate or severe International HS Severity Score System (IHS4) stage. Adalimumab dose intensification significantly improved IHS4 score, Pain Index, HS-Physician Global Assessment, pain, and Cardiff Dermatology Life Quality Index. Two young female patients with HS and Crohn's disease developed psoriatic lesions during the treatment with adalimumab 80 mg/week s.c. Conclusion: An enhanced level of effectiveness was assessed in the majority of the HS patients treated with adalimumab dose intensification (80 mg/week s.c.). Larger studies are required to evaluate this observation.
AB - Background: Adalimumab is the only approved compound for the treatment of adult patients with moderate-to-severe hidradenitis suppurativa (HS) who did not respond to a systemic classical treatment. Despite its significant short- and long-term efficacy, a percentage of patients do not respond sufficiently. Moreover, some primary responders experience a response loss with time. Objective: To analyse the effectiveness of adalimumab dose intensification in HS patients. Methods: A case series of adalimumab 80 mg/week subcutaneously (s.c.) compassionate use in patients with HS, who did not respond sufficiently or in primary responders with progressive response loss to the registered adalimumab dose of 40 mg/week s.c. Patients were collected and evaluated retrospectively. Patients' data were extracted from medical records. Results: The 14 patients collected were Caucasian with HS of Hurley stage II-III and moderate or severe International HS Severity Score System (IHS4) stage. Adalimumab dose intensification significantly improved IHS4 score, Pain Index, HS-Physician Global Assessment, pain, and Cardiff Dermatology Life Quality Index. Two young female patients with HS and Crohn's disease developed psoriatic lesions during the treatment with adalimumab 80 mg/week s.c. Conclusion: An enhanced level of effectiveness was assessed in the majority of the HS patients treated with adalimumab dose intensification (80 mg/week s.c.). Larger studies are required to evaluate this observation.
KW - Acne inversa
KW - Adalimumab
KW - Hidradenitis suppurativa
KW - Intensification
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85074283405&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074283405&partnerID=8YFLogxK
U2 - 10.1159/000503606
DO - 10.1159/000503606
M3 - Article
C2 - 31630144
AN - SCOPUS:85074283405
VL - 236
SP - 25
EP - 30
JO - Dermatology
JF - Dermatology
SN - 1018-8665
IS - 1
ER -